BioSpace News Archive

Drug Development

XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus

The 514G3 antibody was a naturally occurring antibody derived from a healthy individual with highly targeted immunity against S. aureus capable of neutralizing all strains of the bacteria, including a drug-resistant or so-called MRSA form.

January 25, 2018
·
3 min read
Biotech Bay

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150M of Common Stock

The offering is expected to close on or about January 29, 2018, subject to customary closing conditions.

January 25, 2018
·
5 min read
Business

CURE Pharmaceutical Adds New VP of Strategy and Business Development

Dr. Gigi will oversee CURE’s strategy to deliver sustained growth and diversified revenue.

January 25, 2018
·
2 min read
Pixium Vision Completes World’s First Successful Activation in Human of PRIMA Bionic Vision System

Pixium Vision announces today the world’s first successful human implantation and activation of PRIMA, its new generation miniaturized wireless photovoltaic sub-retinal implant, in a patient with severe vision loss from atrophic dry Age-related Macular Degeneration (AMD).

January 25, 2018
·
6 min read
Drug Development

Juntendo University Research: Cognitive Neuroscience: the Awareness of Ignorance

Monkeys were presented with a metacognition task composed of a memory and a bet stage.

January 25, 2018
·
6 min read
Policy

Mariner Endosurgery Receives Health Canada Investigational Testing Approval for LaparoGuard Technology

Dr. Niv Sne, trauma surgeon proficient in advanced laparoscopic cases with Hamilton Health Sciences and Associate Professor of Surgery at McMaster University is the principal investigator for the initial studies.

January 25, 2018
·
1 min read
Biotech Bay

Achaogen Announces New Employment Inducement Grants - Jan. 25, 2018

The compensation committee of the Company’s board of directors granted six new employees the option to purchase an aggregate of 30,000 shares of the Company’s common stock and 15,001 restricted stock units.

January 25, 2018
·
1 min read
Business

Meridian Bioscience Reports First Quarter 2018 Operating Results, Declares Regular First Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance

The company reported first quarter net revenues of $52.3 million, an increase of 12% from the same period of the prior fiscal year.

January 25, 2018
·
17 min read
Pharm Country

Athenex Announces Pricing of Offering of Common Stock

In addition, Athenex has granted the underwriters a 30-day option to purchase up to an additional 645,000 shares of common stock at the same price.

January 25, 2018
·
3 min read
Drug Development

Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial

PhaseOut DMD is evaluating the utrophin modulator ezutromid in patients with Duchenne muscular dystrophy (‘DMD’). The focus of the planned interim analysis was on biopsy measures that show:

January 25, 2018
·
11 min read